Clinical trial · no report yet · Phase 3
DESTINY-BTC01
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- NCT06467357 ↗
- Recruiting
- AstraZeneca
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Gemcitabine; Cisplatin; Durvalumab; Trastuzumab deruxtecan; Rilvegostomig
- Arms
- Trastuzumab deruxtecan + rilvegostomig · Experimental
- Trastuzumab deruxtecan · Experimental
- Standard of Care · Active comparator
- Enrollment
- 620 (estimated)
- Primary outcomes
- Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig
- Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) population
- Sponsor
- AstraZeneca
- Start
- Aug 12, 2024
- Primary completion
- Jun 12, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06467357 · updated Aug 19, 2026